bluebird bio Stock News

The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.

bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.

bluebird bio Inc (NASDAQ:BLUE) may have secured FDA approval for its sickle cell disease cell therapy, Lyfgenia, but market reactions have been mixed. Despite the FDA greenlight, BLUE shares experienc

CNBC's Angelica Peebles reports on the latest news in bioscience.

The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.

Bluebird Bio Inc (NASDAQ:BLUE) stock is enjoying a boost today, after an upgrade from Morgan Stanley to "equal-weight" from "underweight," with a price-target hike to $7.00 from $3.00.

Madrigal aims to offer a treatment in an area where success has eluded many peers. Bluebird Bio is closing in on its third U.S. approval for a gene-editing therapy.

bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.

bluebird bio specializes in gene therapies for severe genetic diseases and has two FDA-approved products. The company has a PDUFA date of December 20 for the approval of lovo-cel for sickle cell disea

Some of the hottest opportunities can be found in biotech stocks. Look at gene editing companies, like CRISPR Therapeutics (NASDAQ: CRSP ), for example.

Biotech stocks with major catalysts can be powerful capital appreciation vehicles. Bluebird Bio and Structure Therapeutics both have significant events scheduled for next month.

The biotech unveiled its latest set of quarterly figures. With two recently commercialized medicines, its revenue leaped significantly higher on a year-over-year basis.

bluebird bio (BLUE) reports better-than-expected results in the third quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene aut

bluebird bio, Inc. (BLUE) Q3 2023 Earnings Call Transcript

Bluebird Bio has experienced a barrage of issues in the past five years. The biotech has a potential approval on the way that could help it rebound.